Evidence map›Paper›PMID 32271161›Full record

ArticleJCI insight2020

Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors.

Paul Dembny, Andrew G Newman, Manvendra Singh, Michael Hinz, Michal Szczepek, Christina Krüger, Robert Adalbert, Omar Dzaye, Thorsten Trimbuch, Thomas Wallach and 16 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 130 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. ERVK activity in CD8Journal of neuroinflammation · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 4 countries.

Paul DembnyInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Andrew G NewmanInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Manvendra SinghMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Michael HinzMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Michal SzczepekInstitute for Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.
Christina KrügerInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Robert AdalbertRoyal Veterinary College, London, United Kingdom.
Omar DzayeMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Thorsten TrimbuchNeuroCure Cluster of Excellence.
Thomas WallachInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Gunnar KleinauInstitute for Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.
Katja DerkowInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Bernhard C RichardDepartment of Neuropathology.
Carola SchipkeDepartment of Psychiatry and Psychotherapy, and.
Claus ScheidereitMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Harald StachelscheidCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, BIH, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.
Douglas GolenbockDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Oliver PetersDepartment of Psychiatry and Psychotherapy, and.
Michael ColemanBabraham Institute and John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Frank L HeppnerNeuroCure Cluster of Excellence.
Patrick ScheererInstitute for Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.
Victor TarabykinInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Klemens RuprechtDepartment of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.
Zsuzsanna IzsvákMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Jens MayerInstitute of Human Genetics, Universität des Saarlandes, Hamburg, Germany.
Seija LehnardtInstitute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Humboldt-Universität zu Berlin · DEMax Delbrück Center · DEGerman Center for Neurodegenerative Diseases · DEBabraham Institute · GBInstitute of Human Genetics · PLRoyal Veterinary College · GBUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although human endogenous retroviruses (HERVs) represent a substantial proportion of the human genome and some HERVs, such as HERV-K(HML-2), are reported to be involved in neurological disorders, little is known about their biological function. We report that RNA from an HERV-K(HML-2) envelope gene region binds to and activates human Toll-like receptor (TLR) 8, as well as murine Tlr7, expressed in neurons and microglia, thereby causing neurodegeneration. HERV-K(HML-2) RNA introduced into the cerebrospinal fluid (CSF) of either C57BL/6 wild-type mice or APPPS1 mice, a mouse model for Alzheimer's disease (AD), resulted in neurodegeneration and microglia accumulation. Tlr7-deficient mice were protected against neurodegenerative effects but were resensitized toward HERV-K(HML-2) RNA when neurons ectopically expressed murine Tlr7 or human TLR8. Transcriptome data sets of human AD brain samples revealed a distinct correlation of upregulated HERV-K(HML-2) and TLR8 RNA expression. HERV-K(HML-2) RNA was detectable more frequently in CSF from individuals with AD compared with controls. Our data establish HERV-K(HML-2) RNA as an endogenous ligand for species-specific TLRs 7/8 and imply a functional contribution of human endogenous retroviral transcripts to neurodegenerative processes, such as AD.

Indexed as

Alzheimer DiseaseEndogenous RetrovirusesMembrane GlycoproteinsRNA, ViralToll-Like Receptor 7Toll-Like Receptor 8AnimalsDisease Models, AnimalHumansMiceMice, KnockoutMembrane GlycoproteinsRNA, ViralTlr7 protein, mouseTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8Alzheimer’s diseaseImmunologyInnate immunityNeurodegenerationNeuroscience

Identifiers

PMID32271161
PMCPMC7205273
OpenAlexW3015549321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.